Download PDF

Education

Publications

Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, et al. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. J Drugs Dermatol. 2015;14:821-33.

 

Stefansson, H., Tryggvadottir, L., Olafsdottir, E. J., Mooney, E., et al. Cutaneous melanoma in Iceland: changing Breslow's tumour thickness. J Eur Acad Dermatol Venereol 29, 346-352 (2015).

Stacey, S. N., Helgason, H., Gudjonsson, S. A., Thorleifsson, G., et al. New basal cell carcinoma susceptibility loci. Nat Commun 6, 6825 (2015).

Sigurgeirsson, B., Boznanski, A., Todd, G., Vertruyen, A., et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 135, 597-606 (2015). 

Baran, R. & Sigurgeirsson, B. Psoriatic nail disease, a predictor of psoriatic arthritis. Br J Dermatol 171, 935-936 (2014).

 Stacey, S. N., Sulem, P., Gudbjartsson, D. F., Jonasdottir, A., et al. Germline sequence variants in TGM3 and RGS22 confer risk of basal cell carcinoma. Hum Mol Genet 23, 3045-3053 (2014).

 Sigurgeirsson, B., Kircik, L., Nemoto, O., Mikazans, I., et al. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. J Eur Acad Dermatol Venereol 28, 1127-1129 (2014).

 Sigurgeirsson, B. & Baran, R. The prevalence of onychomycosis in the global population - a literature study. J Eur Acad Dermatol Venereol 28, 1480-1491 (2014).

 Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med 371, 326-338 (2014).

 Eysteinsdóttir, J. H., Ólafsson, J. H., Agnarsson, B. A., Lúðvíksson, B. R. & Sigurgeirsson, B. Psoriasis treatment: faster and long-standing results after bathing in geothermal seawater. A randomized trial of three UVB phototherapy regimens. Photodermatol Photoimmunol Photomed 30, 25-34 (2014).

 Rich, P., Sigurgeirsson, B., Thaci, D., Ortonne, J. P., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168, 402-411 (2013).

 Papp, K. A., Langley, R. G., Sigurgeirsson, B., Abe, M., et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168, 412-421 (2013).

 Sigurgeirsson, B., van Rossem, K., Malahias, S. & Raterink, K. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol 69, 416-425 (2013).

 Elewski, B. E., Ghannoum, M. A., Mayser, P., Gupta, A. K., et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol 27, 287-294 (2013).

 Iles, M. M., Law, M. H., Stacey, S. N., Han, J., et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet 45, 428-32, 432e1 (2013).

 Eysteinsdóttir, J. H., Sigurgeirsson, B., Ólafsson, J. H., Fridriksson, T., et al. The role of Th17/Tc17 peripheral blood T cells in psoriasis and their positive therapeutic response. Scand J Immunol 78, 529-537 (2013).

 Sigurgeirsson, B. & Ghannoum, M. Therapeutic potential of TDT 067 (terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis. Expert Opin Investig Drugs 21, 1549-1562 (2012).

 Thorleifsdottir, R. H., Sigurdardottir, S. L., Sigurgeirsson, B., Olafsson, J. H., et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol 188, 5160-5165 (2012).

 Sigurgeirsson, B. & Wulf, H. C. [UV-index in Iceland during the summer of 2010]. Laeknabladid 97, 413-416 (2011).

 Sigurgeirsson, B. & Wulf, H. C. [Erythemogenic UV rays]. Laeknabladid 97, 417-420 (2011).

 Stacey, S. N., Sulem, P., Jonasdottir, A., Masson, G., et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 43, 1098-1103 (2011).

 Héry, C., Tryggvadóttir, L., Sigurdsson, T., Olafsdóttir, E., et al. A melanoma epidemic in Iceland: possible influence of sunbed use. Am J Epidemiol 172, 762-767 (2010).

 Sigurgeirsson, B. Prognostic factors for cure following treatment of onychomycosis. J Eur Acad Dermatol Venereol 24, 679-684 (2010).

 Sigurgeirsson, B., Olafsson, J. H., Steinsson, J. T., Kerrouche, N. & Sidou, F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol 24, 910-915 (2010).

 Rafnar, T., Sulem, P., Stacey, S. N., Geller, F., et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 41, 221-227 (2009).

 Stacey, S. N., Sulem, P., Masson, G., Gudjonsson, S. A., et al. New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 41, 909-914 (2009).

 Kong, A., Steinthorsdottir, V., Masson, G., Thorleifsson, G., et al. Parental origin of sequence variants associated with complex diseases. Nature 462, 868-874 (2009).

 Sigurgeirsson, B., Ho, V., Ferrándiz, C., Andriano, K., et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol 22, 1290-1301 (2008).

 Goldstein, A. M., Stacey, S. N., Olafsson, J. H., Jonsson, G. F., et al. CDKN2A mutations and melanoma risk in the Icelandic population. J Med Genet 45, 284-289 (2008).

 Sulem, P., Gudbjartsson, D. F., Stacey, S. N., Helgason, A., et al. Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet 40, 835-837 (2008).

 Gudbjartsson, D. F., Sulem, P., Stacey, S. N., Goldstein, A. M., et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 40, 886-891 (2008).

 Stacey, S. N., Gudbjartsson, D. F., Sulem, P., Bergthorsson, J. T., et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet 40, 1313-1318 (2008).

 Baran, R., Sigurgeirsson, B., de Berker, D., Kaufmann, R., et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 157, 149-157 (2007).

 Scher, R. K., Tavakkol, A., Sigurgeirsson, B., Hay, R. J., et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 56, 939-944 (2007).

 Sulem, P., Gudbjartsson, D. F., Stacey, S. N., Helgason, A., et al. Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet 39, 1443-1452 (2007).

 Sigurgeirsson, B., Elewski, B. E., Rich, P. A., Opper, C., et al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat 17, 38-44 (2006).

 Sigurgeirsson, B., Kristinsson, K. G. & Jonasson, P. S. Onychomycosis in Icelandic children. J Eur Acad Dermatol Venereol 20, 796-799 (2006).

 Hilmarsdottir, I., Haraldsson, H., Sigurdardottir, A. & Sigurgeirsson, B. Dermatophytes in a swimming pool facility: difference in dermatophyte load in men's and women's dressing rooms. Acta Derm Venereol 85, 267-268 (2005).

 Davidsson, S., Blomqvist, K., Molin, L., Mørk, C., et al. Lifestyle of Nordic people with psoriasis. Int J Dermatol 44, 378-383 (2005).

 Roujeau, J. C., Sigurgeirsson, B., Korting, H. C., Kerl, H. & Paul, C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 209, 301-307 (2004).

 Zachariae, R., Zachariae, H., Blomqvist, K., Davidsson, S., et al. Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol 18, 27-36 (2004).

 Sigurgeirsson, B. & Steingrímsson, O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol 18, 48-51 (2004).

 Sigurgeirsson, B. [The darker side of tanning [Editorial].]. Laeknabladid 90, 536-538 (2004).

 Rafnsson, V., Hrafnkelsson, J., Tulinius, H., Sigurgeirsson, B. & Olafsson, J. H. Risk factors for malignant melanoma in an Icelandic population sample. Prev Med 39, 247-252 (2004).

 Olafsson, J. H., Sigurgeirsson, B. & Baran, R. Combination therapy for onychomycosis. Br J Dermatol 149 Suppl 65, 15-18 (2003).

 Gudjonsson, J. E., Thorarinsson, A. M., Sigurgeirsson, B., Kristinsson, K. G. & Valdimarsson, H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 149, 530-534 (2003).

 Rafnsson, V., Hrafnkelsson, J., Tulinius, H., Sigurgeirsson, B. & Olafsson, J. H. Risk factors for cutaneous malignant melanoma among aircrews and a random sample of the population. Occup Environ Med 60, 815-820 (2003).

 Zachariae, H., Zachariae, R., Blomqvist, K., Davidsson, S., et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82, 108-113 (2002).

 Sigurgeirsson, B., Steingrímsson, O. & Sveinsdóttir, S. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 82, 467-469 (2002).

 Sigurgeirsson, B., Olafsson, J. H., Steinsson, J. B., Paul, C., et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 138, 353-357 (2002).

 Zachariae, R., Zachariae, H., Blomqvist, K., Davidsson, S., et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 146, 1006-1016 (2002).

 Sigurgeirsson, B., Paul, C., Curran, D. & Evans, E. G. Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. Br J Dermatol 147, 1241-1243 (2002).

 Zachariae, H., Zachariae, R., Blomqvist, K., Davidsson, S., et al. Treatment of psoriasis in the Nordic countries: a questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study. Acta Derm Venereol 81, 116-121 (2001).

 Hill, C. L., Zhang, Y., Sigurgeirsson, B., Pukkala, E., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357, 96-100 (2001).

 Lindelöf, B., Sigurgeirsson, B., Gäbel, H. & Stern, R. S. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143, 513-519 (2000).

 Gudnadóttir, G., Hilmarsdóttir, I. & Sigurgeirsson, B. Onychomycosis in Icelandic swimmers. Acta Derm Venereol 79, 376-377 (1999).

 Evans, E. G. & Sigurgeirsson, B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 318, 1031-1035 (1999).

 Sigurgeirsson, B., Billstein, S., Rantanen, T., Ruzicka, T., et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. Br J Dermatol 141 Suppl 56, 5-14 (1999).

 Lindelöf, B., Sigurgeirsson, B., Tegner, E., Larkö, O., et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 141, 108-112 (1999).

 Hannuksela-Svahn, A., Sigurgeirsson, B., Pukkala, E., Lindelöf, B., et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 141, 497-501 (1999).

 Gudmundsdottir, A. S., Sigmundsdottir, H., Sigurgeirsson, B., Good, M. F., et al. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 117, 580-586 (1999).

 Lindelöf, B., Hedblad, M. A. & Sigurgeirsson, B. Melanocytic naevus or malignant melanoma? A large-scale epidemiological study of diagnostic accuracy. Acta Derm Venereol 78, 284-288 (1998).

 Lindelöf, B., Hedblad, M. A. & Sigurgeirsson, B. On the association between vitiligo and malignant melanoma. Acta Derm Venereol 78, 483-484 (1998).

 Sigmundsdottir, H., Sigurgeirsson, B., Troye-Blomberg, M., Good, M. F., et al. Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol 45, 688-697 (1997).

 Allander, E., Bring, J., Gudmundsson, L., Mattson, S., et al. What is the long term value of multiphasic health screening and the initial judgement of benefit? Scand J Soc Med Suppl 51, 1-20 (1997).

 Olafsson, J. H., Sigurgeirsson, B. & Pálsdóttir, R. Psoriasis treatment: bathing in a thermal lagoon combined with UVB, versus UVB treatment only. Acta Derm Venereol 76, 228-230 (1996).

 Baldursson, B., Sigurgeirsson, B. & Lindelöf, B. Venous leg ulcers and squamous cell carcinoma: a large-scale epidemiological study. Br J Dermatol 133, 571-574 (1995).

 Sigurgeirsson, B., Agnarsson, B. A. & Lindelöf, B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ 308, 13-15 (1994).

 Eiríksson, T. H., Sigurgeirsson, B., Ardal, B., Sigfússon, A. & Valdimarsson, H. Cord blood IgE levels are influenced by gestational age but do not predict allergic manifestations in infants. Pediatr Allergy Immunol 5, 5-10 (1994).

 Baldursson, B., Sigurgeirsson, B. & Lindelöf, B. Leg ulcers and squamous cell carcinoma. An epidemiological study and a review of the literature. Acta Derm Venereol 73, 171-174 (1993).

 Gunnarskog, J. G., Källén, A. J., Lindelöf, B. G. & Sigurgeirsson, B. Psoralen photochemotherapy (PUVA) and pregnancy. Arch Dermatol 129, 320-323 (1993).

 Lindelöf, B. & Sigurgeirsson, B. PUVA and cancer: a case-control study. Br J Dermatol 129, 39-41 (1993).

 Sigurgeirsson, B. Skin disease and malignancy. An epidemiological study. Acta Derm Venereol Suppl (Stockh) 178, 1-110 (1992).

 Lindelöf, B., Sigurgeirsson, B., Tegner, E., Larkö, O. & Berne, B. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report. Arch Dermatol 128, 1341-1344 (1992).

 Lindelöf, B., Sigurgeirsson, B. & Melander, S. Seborrheic keratoses and cancer. J Am Acad Dermatol 26, 947-950 (1992).

 Sigurgeirsson, B., Lindelöf, B., Edhag, O. & Allander, E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326, 363-367 (1992).

 Lindelöf, B. & Sigurgeirsson, B. PUVA treatment in Sweden. Acta Derm Venereol Suppl (Stockh) 169, 3-6 (1991).

 Sigurgeirsson, B. & Lindelöf, B. Lichen planus and malignancy. An epidemiologic study of 2071 patients and a review of the literature. Arch Dermatol 127, 1684-1688 (1991).

 Sigurgeirsson, B., Lindelöf, B. & Eklund, G. Condylomata acuminata and risk of cancer: an epidemiological study. BMJ 303, 341-344 (1991).

 Sigurgeirsson, B. CANEST: a microcomputer program for estimating cancer in a cohort. Comput Methods Programs Biomed 35, 193-201 (1991).

 Lindelöf, B., Sigurgeirsson, B., Wallberg, P. & Eklund, G. Occurrence of other malignancies in 1973 patients with basal cell carcinoma. J Am Acad Dermatol 25, 245-248 (1991).

 Lindelöf, B., Sigurgeirsson, B., Tegner, E., Larkö, O., et al. PUVA and cancer: a large-scale epidemiological study. Lancet 338, 91-93 (1991).

 Lindelöf, B., Sigurgeirsson, B., Wahlgren, C. F. & Eklund, G. Chronic urticaria and cancer: an epidemiological study of 1155 patients. Br J Dermatol 123, 453-456 (1990).

 Sigurgeirsson, B., Jóhannsson, K. B., Haroarson, S., Onundarson, P. T. & Thorgeirsson, G. Acute thoracic inlet obstruction in achalasia with adenoid cystic and squamous cell carcinoma. Ann Thorac Surg 40, 516-518 (1985).

Positions after medical examination

National University Hospital, Reykjavik, Iceland: Various clinics 1982-1984National University Hospital, Reykjavik, Iceland:Department of Clinical Immunology 1984-1988Karolinska Hospital, Stockholm, Sweden, Department of Dermatology, 1988-1992Landspitali University Hospital, Dept.  Dermatology 1992-2003Grund, Nursing Home,  Consulting specialist in Dermatology 1991-Private practice,  in Reykjavik  1991-1998

Húðlæknastöðin (Dermatology Center) from 1998The Blue lagoon psoriasis treatment centre, Iceland, Chief physician 1994-2004

Advisory Boards

Novartis

Schering-Plough

ProStrakan

Arpida

Galderma

Stiefel

Celtic pharma

Teaching experience

Karolinska Institute Stockholm, clinical teaching 1988-1991University of Iceland, Lecturer in Dermatology 1992-1998

University of Iceland, Assistant Professor of  Dermatology 1998-

GCP

Trained for ICH Good Clinical Practice and has participated in several clinical studies conducted under ICH GCP.

Therapeutic area experience includes fungal infections, psoriasis, eczematous disorders, rosacea and hip fractures.

Several courses and training sessions on GCP. At least annually from 1995, both in Iceland and abroad.

Grants

The Icelandic research Council, Reykjavik, IcelandTo study the relationship between cord blood IgE and Atopy. 1986

The Karolinska Hospital, Stockholm, SwedenTo work on a thesis: the relationship between Skin disease and Malignancy, 1991The Edvard Welander Foundation, Sweden

To study the relationship between dermatitis herpetiformis and other skin diseases and malignancy, 1993The Edvard Welander Foundation, Sweden

To study the relationship between pemphigus and other skin diseases and malignancy, 1994The Icelandic research Council, Reykjavik, Iceland

To study the relationship between skin disease and malignancy 199. 2The Icelandic research Council, Reykjavik, Iceland

For continuing development of a computer program for cancer research and study the relationship between skin disease and malignancy, 1994, Sandoz pharmaceutical corporation

To study the epidemiology of onychomycosis in Iceland, 1994. The ministry of Health, IcelandTo study the epidemiology of onychomycosis in Iceland, 1994